Basic analysis of anti-allergic agent MMKY-01, which accelerating drug sensitivity to gemicitabine in pancreatic cancer cell.
| Project/Area Number |
20591632
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Saga University |
|---|
Principal Investigator |
KITAJIMA Yoshihiko Saga University, 医学部, 客員研究員 (30234256)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2010: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
|---|
| Keywords | 膵癌 / 胆嚢癌 / ジェムシタビン / MMKY-01 / RRM1 / ユビキチン / TGF-β / ジェムシタビン耐性 / GB-d1R / TGF-beta / cDNAアレイ / アポトーシス / MMYK-01 / ジェムシタビン(GEM) / GEM耐性株 / DNAアレイ / 増強効果 |
|---|
| Research Abstract |
The present study demonstrated that MMKY-01 accelerates drug sensitivity to gemcitabine via decreasing RRM1 expression in pancreatic and gall bladder (GB) cancer cells. The reduced RRM1 expression was derived through ubiquitin-proteosome pathway in pancreatic cancer. Further analysis revealed that MMKY-01 rendered gemcitabine resistant GB cancer cell to apoptosis. These results indicated that MMKY-01 plus gemcitabine is possibly effective to pancreatic as well as GB cancer. Especially, MMKY-01 treatment was revealed to reverse the gemcitabine resistance in GB cancer.
|
Report
(4 results)
Research Products
(13 results)
